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Alzheimer’s disease (AD) and mixed dementia (MxD) comprise the majority of dementia
cases in the growing global aging population. MxD describes the coexistence
of AD pathology with vascular pathology, including cerebral small vessel disease
(SVD). Cardiovascular disease increases risk for AD and MxD, but mechanistic
synergisms between the coexisting pathologies affecting dementia risk, progression
and the ultimate clinical manifestations remain elusive. To explore the additive or
synergistic interactions between AD and chronic hypertension, we developed a
rat model of MxD, produced by breeding APPswe/PS11E9 transgenes into the
stroke-prone spontaneously hypertensive rat (SHRSP) background, resulting in the
SHRSP/FAD model and three control groups (FAD, SHRSP and non-hypertensive
WKY rats, n = 8–11, both sexes, 16–18 months of age). After behavioral testing,
rats were euthanized, and tissue assessed for vascular, neuroinflammatory and AD
pathology. Hypertension was preserved in the SHRSP/FAD cross. Results showed that
SHRSP increased FAD-dependent neuroinflammation (microglia and astrocytes) and
tau pathology, but plaque pathology changes were subtle, including fewer plaques
with compact cores and slightly reduced plaque burden. Evidence for vascular
pathology included a change in the distribution of astrocytic end-foot protein aquaporin-
4, normally distributed in microvessels, but in SHRSP/FAD rats largely dissociated
from vessels, appearing disorganized or redistributed into neuropil. Other evidence
of SVD-like pathology included increased collagen IV staining in cerebral vessels
and PECAM1 levels. We identified a plasma biomarker in SHRSP/FAD rats that
was the only group to show increased Aqp-4 in plasma exosomes. Evidence of
neuron damage in SHRSP/FAD rats included increased caspase-cleaved actin, loss
of myelin and reduced calbindin staining in neurons. Further, there were mitochondrial
deficits specific to SHRSP/FAD, notably the loss of complex II, accompanying FAD-
dependent loss of mitochondrial complex I. Cognitive deficits exhibited by FAD
rats were not exacerbated by the introduction of the SHRSP phenotype, nor was
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the hyperactivity phenotype associated with SHRSP altered by the FAD transgene.
This novel rat model of MxD, encompassing an amyloidogenic transgene with a
hypertensive phenotype, exhibits several features associated with human vascular or
“mixed” dementia and may be a useful tool in delineating the pathophysiology of MxD
and development of therapeutics.
Keywords: cerebrovascular integrity, tau pathogenesis, Alzheimer disease, vascular dementia, rat model
INTRODUCTION
The Continuum Between Alzheimer’s
Disease, Vascular and Mixed Dementia
The number of people living with dementia globally is projected
to reach 81 million by 2040 (Ferri et al., 2005), while cases of
Alzheimer’s disease (AD), estimated to be the most prevalent
dementia type, are predicted to exceed 13.8 million by 2050 in
the United States (Hebert et al., 2013) and 81 million globally
(Rizzi et al., 2014; Baumgart et al., 2015), translating to an
economic burden associated with dementia of over $800 billion
(Wimo et al., 2013, 2017). Despite reports that AD is the most
common dementia with an incidence of 50–64%, pure AD is
rare as shown in the Religious Orders Study, with a prevalence
of only 10%. One reason for this discrepancy is that 60–90%
of those diagnosed with Alzheimer’s dementia are found at
autopsy to have coexisting cerebrovascular disease (CBVD) and
may or may not be diagnosed with mixed dementia (MxD).
CBVD pathologies include white matter lesions, microvascular
degeneration, microinfarcts and vascular amyloid (Kalaria et al.,
2012). Mixed dementia (MxD) refers to the coexistence of
vascular pathology with dementia, and the diagnosis depends
on the severity of vascular pathology and diagnostic criteria.
There may be cortical or subcortical tissue loss, but in all cases
of MxD, cerebral small vessel disease (SVD) is evident (Khan
et al., 2016; Vinters et al., 2018). Due to the varied criteria for
classifying dementia cases as MxD, the incidence is debatable,
as reports range widely from 2 to 58%, averaging around 20 to
22% (Jellinger and Attems, 2007; Custodio et al., 2017). Incidence
rates at the lower end of this range are usually reported by studies
with younger subjects (less prone to MxD) or more rigorous
criteria, such as different cutoffs for minimum infarct volume
and exclusion of cases with cerebral amyloid angiopathy (CAA)
from the criteria.
Critical gaps in knowledge include a paucity of understanding
the potential synergism between tau, amyloid and vascular
pathology and how this may increase vulnerability to central
nervous system (CNS) damage. Vascular pathology in the
clinically normal elderly is associated with impaired episodic
memory independent of medial temporal atrophy (Wennberg
et al., 2019). Furthermore, data from the Honolulu-Asian Aging
cohort suggest that the dementia frequency in cognitively normal
men more than doubles with increased cerebrovascular lesions
accompanied by augmented tau pathology and surprisingly fewer
neuritic plaques (Petrovitch et al., 2005), but the manner in which
subclinical levels of AD and vascular pathology impacts dementia
risk is unclear.
Cardiovascular Disease Increases Risk
for Alzheimer’s Disease and Vascular
Dementia
Elevated blood pressure is strongly associated with AD, and mid-
life hypertension correlates with greater subsequent cognitive
decline (Launer et al., 2000; Petrovitch et al., 2000; Gottesman
et al., 2014). Cognitively normal subjects with uncontrolled
hypertension show increased amyloid and dementia incidence,
particularly in ApoE4 carriers (Rodrigue et al., 2013; Yasar et al.,
2013; Oberlin et al., 2015; Walker et al., 2017). Treatment of
vascular risk factors may slow decline in AD (Valenti et al., 2014),
as suggested by the multi-domain trial in Finnish patients with
AD and high CBVD risk (Ngandu et al., 2015). Together these
data suggest a meaningful association between cardiovascular
health, CBVD, AD and dementia.
Efficacy of drugs directed at pure AD may be attenuated
or contraindicated by the presence of CBVD. For example,
AD subjects with vascular pathology, such as acute or
sub-acute micro-hemorrhage or superficial siderosis, may
experience more adverse effects with amyloid-clearing drugs
such as anti-amyloid vaccination and may therefore be
excluded from clinical trials (Sevigny et al., 2016). Further,
a meta-analysis showed memantine to be beneficial after
6 months in moderate to severe AD, but not in patients
with mild to moderate vascular dementia (VaD) (Areosa
et al., 2005). For these reasons, many AD drug trials
deliberately exclude patients with neuroimaging indices of
vascular pathology while drug development generally neglects
the assessment of efficacy in models of MxD, a major real world
patient population.
Vascular Pathologies and Mechanisms in
Mixed Dementia
The molecular mechanisms underlying VaD affect pathogenesis
in MxD are unknown. For example, VaD may accelerate
AD pathogenesis, including tau and amyloid pathology, by
interrupting normal clearance of these proteins from the brain
and impeding blood and interstitial fluid flow as a result
of vasomotor tone dysregulation (Di Marco et al., 2015;
Iadecola, 2016). Alternatively, AD may exacerbate CBVD by
contributing to vasoconstriction leading to hypoxia and infarct
(Marfany et al., 2018). Some studies suggest that deficient vessel
integrity from chronic hypertension decreases cerebral blood
flow, leading to hypoperfusion of the brain, protein misfolding
and reduced clearance of Aβ and other toxins (de la Torre, 2012).
Chronically elevated arterial pressure also leads to thickening of
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cerebral vessel walls with increased collagen deposition (Zhou
et al., 2015), reduced elasticity and narrowing of the lumen
(Heagerty et al., 2010). This is especially apparent in small
vessels (Feihl et al., 2008; Heagerty et al., 2010), particularly
those of the cerebrovasculature (Grinberg and Thal, 2010). The
brains of AD patients contain smaller blood vessels, exhibiting
reduced density, length and diameter, effects that are especially
evident in the vicinity of senile plaques (Bouras et al., 2006;
Kitaguchi et al., 2007). Pathologies associated with CBVD include
microvascular degeneration, periventricular venous collagenosis
and increased vessel tortuosity (Moody et al., 1995; Farkas
et al., 2000). Synergistic versus additive effects of CBVD on
AD pathogenesis and cognitive decline are not fully understood
(Attems and Jellinger, 2014).
Distinguishing Alzheimer’s Disease From
Mixed Dementia
There is no consensus on the neuropsychological parameters that
differentiate AD from MxD (Planton et al., 2017; Ramirez-Gomez
et al., 2017), although subjects with subcortical ischemic vascular
disease, including small vessel disease, commonly show increased
difficulty in executive function, but may respond better than AD
subjects to cues, suggesting improved preservation of recognition
memory, as opposed to AD subjects that have difficulty in coding
or storage of memory (Mendez and Ashla-Mendez, 1991; Lafosse
et al., 1997; Looi and Sachdev, 1999; Lukatela et al., 2000; Traykov
et al., 2002). In addition to impaired executive function, reduced
attention, processing speed, and memory retrieval have been
reported in MxD (Baker et al., 2012).
Neuroimaging findings can be included in the classification
of MxD, but may not necessarily detect mild white matter
intensities (WMI) or SVD, another reason the prevalence of
MxD may be underestimated (Baker et al., 2012). Additionally,
there is no clear consensus on the amount of vascular pathology
identified by neuroimaging required to be clinically significant
(Dey et al., 2016). Alternatively, the SVD score (0–4), based
on white matter hyperintensities, lacunae, microbleeds,
and enlarged perivascular spaces detected by magnetic
resonance imaging (MRI) is sometimes used to define MxD
(Staals et al., 2015).
Although there are NINDS-AIREN and ADDTC criteria for
diagnosing MxD, the former including neuropathology and the
latter requiring both clinical and neuroimaging abnormalities,
there is no clear consensus and no CERAD criteria to define
MxD (Jellinger and Attems, 2007). The pathologies of AD
and VaD often overlap in subcortical regions (basal ganglia,
thalamus, hippocampus and white matter). MxD patients often
exhibit multi-infarcts so one definition of MxD requires that
patients must meet the criteria for AD and have larger and
hemispheral infarcts, reaching 30–50 ml of infarcted volume
(Khan et al., 2016), which may indicate synergism between the
two pathologies and not just two coexisting pathways. Other
groups also include more severe vascular pathology such as
territorial infarcts, lobar hematomas, cortical microbleeds or
even CAA (De Reuck et al., 2018). It is presumed that in MxD
the thresholds for developing dementia may be lowered due
to subclinical levels of both pathologies, or that the presence
of vascular pathology can unmask AD pathology and trigger
dementia (Fischer et al., 1991; Kalaria et al., 2012).
Models of Cerebrovascular Disease
Models of dementia associated with cerebrovascular insufficiency
have typically involved surgical manipulation of the arteries that
supply the brain, to invoke transient or chronic hypertensive
events (Galisova et al., 2014; Kwon et al., 2014; Wang, 2014;
Venkat et al., 2017; Khoshnam et al., 2018; Liu et al., 2018; Yu
et al., 2018). Such invasive procedures invariably introduce a
multitude of potentially confounding factors and inadequately
model the clinical scenario of chronic hypertension. As such,
animal models that accurately recreate the clinical scenario of
MxD are lacking. Induction of hypertension in a pig model and
in 3xTg mice causes shrinkage of hippocampal dendritic arbors,
microglial activation, blood brain barrier (BBB) leakage and
impaired learning and memory, in addition to elevated amyloid
burden (Shih et al., 2018). This suggests that hypertension
leads to AD-like brain pathologies in a naïve animal model,
while induction of hypertension in an amyloidogenic model
can exacerbate pathology further. Hypertension in APP/PS1
mice accelerates progression of AD-like pathologies, including
cognitive dysfunction and amyloid pathology, in addition to
reduced density of microvessels and cerebrovascular dysfunction
(Cifuentes et al., 2015). In naïve APP/PS1 mice, Aβ accumulation
in cerebral blood vessel walls has been demonstrated (Klakotskaia
et al., 2018). Others have observed microangiopathies and
aneurysms throughout the microvessels of the liver, kidneys
and the brain of APP/PS1 mice (Kelly et al., 2015, 2017),
suggesting a causal relationship between amyloidogenesis and
systemic vascular dysfunction, at least in the APP/PS1 mouse.
Hypertension in rats results in BBB dysfunction, cognitive
impairments and white matter lesions, along with fibrinoid
necrosis, hyalinosis and vascular remodeling of small vessels in
the brain (Fan et al., 2015). Downregulation of tight junction
proteins and disturbed tight junction ultrastructure are apparent
in hypertensive rats (Fan et al., 2015; Meissner et al., 2017), and
have also been observed in AD and other inflammatory disorders
of the brain (Coisne and Engelhardt, 2011; Grammas et al.,
2011). Hypertensive cardiovascular disease involves a significant
inflammatory component (Harrison et al., 2011), and mounting
evidence suggests that inflammation-driven endothelial cell
damage leads to BBB breakdown and SVD, an important risk
factor in VaD (Wardlaw et al., 2013).
The selectively inbred spontaneous hypertensive rat (SHR)
was developed in 1963 at Kyoto University and exhibits elevated
systolic blood pressure, cortical and striatal infarcts, along
with white matter damage, BBB dysfunction and gliosis that
progressively worsens (Tayebati et al., 2012; Kaiser et al., 2014;
Venkat et al., 2015). This model also shows evidence of reduced
BBB proteins and enhanced permeability within paraventricular
and brain stem regions (Biancardi et al., 2014; Meissner et al.,
2017) along with progressive elevations of oxidative stress
markers in brain and plasma (Takemori et al., 2013). It is
widely appreciated that the SHR rat represents an excellent
model of essential hypertension leading to cerebral SVD, stroke
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and VaD (Hainsworth and Markus, 2008; Bailey et al., 2009;
Hainsworth et al., 2012; Kaiser et al., 2014). By 6 months of age
SHRs develop SVD along with cognitive deficits, hippocampal
neurodegeneration and white matter loss (Jalal et al., 2012),
detectable by MRI (Koundal et al., 2019). The stroke-prone
SHR (SHRSP) was created in 1974, as a sub-strain of the
SHR with a high incidence of stroke and hypertension (220–
240 mmHg) (Okamoto and Aoki, 1963; Nabika et al., 2012).
By 3–4 months of age these rats develop hypertension, which
causes elevated plasma levels of pro-inflammatory cytokines
(Sicard et al., 2008), and cerebral SVD (Schreiber et al., 2014). In
addition to thickened cerebral small vessel walls, these rats also
develop cognitive dysfunction, including spatial learning deficits,
effects that were ameliorated by COX-2 inhibition (Tang et al.,
2015) as well as demyelination and oligodendrocyte apoptosis
(Jalal et al., 2012; Weaver et al., 2014), suggesting an association
between vascular injury and demyelination, that may be mediated
by inflammation.
The SHRSP rats have been reported to have AD like pathology
with small but significant increases in hyperphosphorylated
tau and Aβ, most notably vascular Aβ associated with the
progressive vessel wall damage, thrombotic occlusions and
reductions of cerebral blood flow in SHRSP (Bueche et al.,
2014; Schreiber et al., 2014; Held et al., 2017; Pirici et al.,
2017; Jandke et al., 2018). However, to date there are no
animal models of dementia with widespread abundant neuritic
plaque pathology and detergent insoluble ptau that incorporate
clinically relevant hypertension, making it difficult to investigate
the interplay between cerebrovascular damage and ptau and
amyloid accumulation.
Purpose of the Study
This study addresses the need for an adequate model of MxD.
Rat models have advantages over mice due to improved cognitive
ability and larger volumes of brain, cerebrospinal fluid and
plasma, which can expedite development of diagnostic and
surrogate imaging and fluid biomarkers. The TgF344-AD rat
model, developed by Cohen and colleagues (Cohen et al.,
2013), expresses human APPswe and PS11E9 mutations and
develops age-dependent cerebral amyloidosis, gliosis and
phospho-tau pathology (Cohen et al., 2013). TgF344-AD
rats also exhibit pronounced cognitive and neuropsychiatric
behavioral abnormalities by 15 months of age, along with
dysregulated neural network activity (Munoz-Moreno et al.,
2018; Stoiljkovic et al., 2018), as well as age-dependent
deterioration of hippocampal synaptic function in this model
(Smith and McMahon, 2018). Mouse models harboring
amyloidogenic transgenes show hyperphosphorylated tau, but
not robust detergent insoluble tau and tangles (tauopathy),
neurodegeneration but not robust neuron loss. Introduction of
human tau or frontotemporal tau dementia mutations can lead
to development of neurofibrillary tangles, but those models do
not precisely recapitulate pathogenesis in AD, in part because
AD patients do not have tau mutations driving tauopathy
(Sydow et al., 2011; Sayed et al., 2018). Here we hypothesized
that the introduction of a hypertensive phenotype in an AD
rat model could exacerbate Aβ and/or tau pathology, gliosis,
vascular pathology and cognitive dysfunction and serve as a new
model of MxD for future studies of mechanism, biomarkers
and therapeutics.
MATERIALS AND METHODS
Animals
The SHRSP/FAD rat model was developed at the UCLA Division
of Laboratory Animal Medicine vivarium, and the colony is
now maintained at the Veterans Affairs Greater Los Angeles
Health Care System. All experimentation was approved by the
UCLA Chancellor’s Animal Research Committee and the Veteran
Administration Institutional Animal Care and Use Committee
and carried out in compliance with National Institutes of
Health guide for the care and use of Laboratory animals (NIH
Publications No. 8023, revised 1978). Rats were bred and housed
in groups of least two under a 12-h light-dark cycle and had
access to standard chow and water ad libitum. Four strains
were used (16–18 month old, females and males): (i) non-
hypertensive WKY (n = 8), (ii) TgF344-AD (FAD) (n = 11), (iii)
hypertensive SHRSP (n = 10) and (iv) SHRSP/FAD (n = 9) rats.
The hypertensive rats in this study were 75:25% SHRSP:F344, and
the non-hypertensive rats had 75%:25% WKY:F344 backgrounds,
and the methods for breeding them described below.
Stroke-Prone Spontaneously Hypertensive Rats With
(SHRSP/FAD) or Without (SHRSP) the FAD Transgene
The founder hypertensive rats (SHRSP) were obtained from
Charles River Laboratories and the original FAD rats, created
at NIH by Dr. Robert Cohen, were obtained directly from
his laboratory at Emory as well as purchased from the Rat
Resource & Research Center, University of Missouri. The FAD
female offspring of the first mating were again crossed with
100% SHRSP males, which produced the SHRSP/FAD litters
used in this study. The SHRSP sub-strain of the SHR, created
in 1974, is considered a robust model of hypertension and
stroke. Although the precise loci are debated, SHRSP genetic
susceptibility for hypertension and cerebral lesions is autosomal
dominantly inherited (Gratton et al., 1998), allowing us to
cross with the TgF344-AD (FAD) rat, producing a novel rat,
expressing autosomal dominant familial AD genes, on the SHRSP
background (SHRSP/FAD).
The founder FAD rats were derived from the FAD rat on an
F344 background, which express human mutant variants of APP
(Swedish) and PS1 (1E9) and develop age-dependent amyloid
pathology, hyperphosphorylation of tau, gliosis and cognitive
dysfunction (Cohen et al., 2013). The current hypertensive FAD
is 98:2% SHRSP:F344 background.
Non-hypertensive Rats With (FAD) or Without (WKY)
FAD Transgene
There were two types of non-hypertensive rats (WKY or
WKY/FAD). Since the background strain of the SHRSP and FAD
rats is WKY and F344, respectively, we bred WKY, the original
background of the SHRSP, into the FAD model. Specifically,
male WKY rats were paired with female FAD rats. The resulting
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background was 50:50% WKY/F344, and rats with the FAD
transgene were again paired with 100% WKY animals, creating
the F2 generation with 75:25% WKY:F344, and the two non-
hypertensive groups (FAD and WKY) that were used for the
study. The current non-hypertensive FAD colony has a 98% WKY
background. The non-hypertensive, non-transgenic control rats
are henceforth described as WKY, while the non-hypertensive,
transgenic controls are described as FAD rats.
Blood Pressure Measurement
Arterial blood pressure was measured in the caudal tail artery
of rats using the CODATM Non-invasive Blood Pressure System
(Kent Scientific, Torrington, CT, United States). Rats were
handled and acclimatized to the apparatus for 15 min daily for
3 days prior to blood pressure measurements. On the fourth day,
rats were allowed to enter the holder freely with as little force
as possible and allowed to remain in place for 15 min. Then
an occlusion cuff was passed over the animal’s tail to the base
and inflated to impede blood flow to the tail. The occlusion cuff
was slowly deflated, while a second tail cuff that incorporates a
volume pressure recording (VPR) sensor was secured to the tail,
distal to the occlusion cuff. The tail of the animal was kept in
contact with a heated platform, while the VPR sensor measured
physiological characteristics of the returning blood flow. As
blood returned to the tail, the VPR sensor cuff measured the
swelling of the tail that results from arterial pulsations from the
blood flow. Systolic blood pressure was automatically measured
at the first appearance of tail swelling. Diastolic blood pressure
is automatically measured when the increasing rate of swelling
ceases in the tail.
Behavioral Testing
Behavioral testing took place in a quiet, dimly lit room and the
testing apparatus was isolated using divider panels. The apparatus
was cleaned with 70% isopropanol between trials to avoid the
accumulation of olfactory cues. Animals were handled in the
testing room for 1 week prior to beginning the experiments, by
the experimenter that performed the testing.
Open Field Task
Locomotor activity and anxiety were assessed in the open field
task (OFT), during which rats were placed into a black box 27.5
inches in width, 27.5 inches in length and with walls 15.5 inches in
height. The arena was dimly lit from above, and rats were allowed
to explore freely for 8 min. The animals’ movements were tracked
with an overhead camera and recorded on AnymazeTM software
(Stoelting, Wood Dale, IL, United States). Path length and speed
were calculated automatically. An independent investigator,
blinded to the identity of the animals, manually counted
defecation, rearing and grooming events.
Novel Object Recognition Task
The OFT was considered the first habituation day for the novel
object recognition task (NOR). The second day of habituation
took place 24 h following the OFT. Rats were returned to the
same box along with two identical objects, secured to the floor,
spaced evenly apart and equidistant from the walls, and allowed
to explore freely for 10 min. The objects were either pipette
tip boxes or filled cell culture flasks and these were alternated
between rats in order to mitigate the effects of preference for
or aversion to either object. Twenty-four hours later, rats were
again placed into the box with the same identical objects and
allowed to explore for 10 min. Rats were then returned to their
cage for an interval of 1 h before being placed, once again,
into the box with two objects. This time one of the objects
was replaced with a previously un-encountered object, either a
tip box or a flask, and the rat was, again, allowed to explore
freely for 10 min. The time spent exploring each object was
measured and recognition indices calculated for each object,
which were then compared to determine whether or not the
animal showed a significant preference for the novel object, an
innate behavior in healthy rats. A discrimination index (DI) was
also calculated for each mouse in the test phase with the equation
(tN – tF)/(tN + tF), where tN equals time spent exploring the
novel object and tF equals time spent exploring the familiar
object. Another measurement of preference was, the recognition
index (RI) calculated by tN/(tN+tF).
Y Maze
The Y maze consisted of three arms and walls 12 inches in height.
Testing took place another day following completion of the NOR
task. The rat was placed into the bottom arm of the Y maze,
designated A and allowed to explore the rest of the maze freely.
The animals’ movements were tracked with an overhead camera
and recorded on Anymaze software, measuring entries into each
arm (A, B, and C). We then calculated corrected arm entries
as those into a “novel” subsequent arm (e.g., A > B > C or
B > C > A or C > B > A). Errors were measured as entries
into a directly previous arm (e.g., A > B > A or C > B > C
or B > A > B). Spontaneous alternation was calculated with the
equation C / (T-1)× 100, where C equals correct arm entries and
T equals total arm entries.
Euthanasia, Plasma and Brain Collection
for Biochemistry and Histology
At the end of the experiment, rats were injected with a lethal
dose of pentobarbital (100 mg/kg i.p.) and upon deep anesthesia,
the chest cavity was opened and rats were perfused intracardially
with a physiologically isotonic buffer containing 10 mM HEPES,
137 mM NaCl, 4.6 mM KCL, 1.1 mM KH2PO4, 0.6 MgSO4,
1.1 mM EDTA, and protease inhibitors (5 mg/ml of leupeptin
and aprotinin and 2 mg/ml pepstatin A, pH 7.4). The brain was
bisected and the hippocampus and cortex were dissected from
the left hemisphere, snap frozen in liquid nitrogen and stored
at −80◦C until use for biochemistry, while the right hemisphere
was immersion-fixed in 4% formalin, sucrose cryopreserved and
frozen at−80◦C until cryosectioning.
Histology
Immunohistochemistry
Coronal sections of frozen rat hemi-brains were cryosectioned
at 12 µm thick, mounted on slides and stored at −20◦C. For
immunohistochemistry (IHC), slides were warmed to room
temperature for 1 h and then steamed for 20 min using
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a citric acid base antigen-unmasking solution (Vector Labs,
Burlingame, CA, United States). Sections were quenched with
hydrogen peroxide (H2O2) in methanol for 30 min at room
temperature, then washed three times with tris buffered saline
(TBS) (pH 7.4) (for staining of Aβ, Tau pS422, collagen-
4) or treated with 0.3% Triton X-100 in 0.1 M TBS (pH
7.4) for 10 min at room temperature (for staining of Aqp-
4, GFAP, Tau pS422, collagen-IV). For Aβ staining, sections
were pretreated with 70% formic acid for 10 min at room
temperature. For all IHC, sections were treated with a blocking
solution, consisting of 1.5–5% normal serum and 3% bovine
serum albumin (BSA) in TBS for 1 h at 37◦C, followed by
incubation with primary antibodies for 1 h at 37◦C, then
overnight at 4◦C. Amyloid-β (Aβ) deposits were labeled with
6E10 (1:500, anti-Aβ) recognizing residues 1-16 (Biolegend,
San Diego, CA, United States). Astrocytic endfeet associated
with capillaries were labeled with anti-Aqp-4 polyclonal (1:200,
NOVUS Biologicals, Littleton, CO, United States) and processes
with anti-GFAP monoclonal (1:5000; Sigma-Aldrich St. Louis,
MO, United States). Anti-calbindin D 28K rabbit polyclonal
antibody (1:800; Thermo Fisher, Asheville, NC, United States)
was used as a neuronal marker. Microglia were labeled with
an anti-Iba1 rabbit polyclonal (1:200; Wako, Richmond, VA,
United States) antibody raised against a synthetic peptide
corresponding to the C-terminus of Iba1. Levels of Tau
phosphorylated at serine 422 (pS422) were detected using
a rabbit polyclonal antibody against MAPT/Tau pS422-Aff-
purified (1:800, Acris, San Diego, CA, United States). Blood
vessels were labeled with anti-collagen IV mouse monoclonal
antibody (Invitrogen, Waltham, MA, United States). Sections
were then incubated with secondary antibodies diluted in
normal serum and 3% BSA for 1 h at 37◦C followed by
avidin-biotin complex (ABC; Vector Labs, Burlingame, CA,
United States) reagent for 1 h 20 min at 37◦C. After ABC
incubation, metal-enhanced peroxidase diaminobenzidine (DAB;
Pierce, Rockford, IL, United States) was used for detection of
positive staining.
Luxol Fast Blue Myelin Staining
The Kluver-Barrera Luxol Fast Blue Method was used to stain
myelin using cryostat sections. Briefly, sections were rinsed in
95% alcohol, then incubated overnight at 60◦C with a 0.1%
solution of Luxol Fast Blue (Solvent Blue 38 Sigma) dissolved in
95% alcohol, 0.5% and ∼10% glacial Acetic Acid, then filtered.
Sections were washed with 95% ethanol, rinsed with distilled
water, then differentiated by quick immersion in 0.05% lithium
carbonate solution, followed by several changes in 70% ethanol
and then rinsed with distilled water. Then sections are incubated
for 6 min with 60◦C filtered 0.1% Cresyl Echt Violet solution in
distilled water with 15 drops of 15% glacial acetic acid added.
Sections were differentiated and acidified (drops of 5N HCL) in
95% alcohol then cleared in CitriSolvTM Solvent and Clearing
Agent (VWR) prior to cover slipping with Thermo ScientificTM
DPX Mounting Media. Evaluation of differences in Luxol Blue
staining patterns was performed by an experimenter blinded
to transgenic animal. Four consecutive coronal sections were
evaluated per rat at Bregma at−4.0.
Western Blot
Brain tissue was weighed before starting protein extraction.
Frozen brain tissues were added to TBS (10 × volume of
brain wet weight) containing complete protease inhibitor (PI)
and phosphatase inhibitor (PPI) cocktail (Roche, Mannheim,
DE, United States) and sonicated for 10 s × 3 times on ice
to disrupt cell membranes. The sonication conditions were
kept the same in all the following steps. After sonication,
samples were centrifuged at 132,000 × g for 20 min at
4◦C to produce TBS supernatant used to measure soluble
proteins. The pellet was further extracted in modified RIPA lysis
buffer with PI and PPI to obtain detergent-soluble membrane
fractions and lysis-insoluble pellets for insoluble tau aggregates.
Lysis pellets were then re-suspended in sample buffer. All the
samples were stored at −80◦C and protein assayed prior to
use. The protein concentration was measured according to
Bio-Rad protocol (Bio-Rad, Hercules, CA, United States). For
western blotting, 15–30 mg of protein was electrophoresed
on a 7.5–12% acrylamide gradient gel, and then transferred
to polyvinylidene fluoride membrane. After blocking in 10%
non-fat milk, blots were incubated with primary antibodies
against Aqp-4 (NOVUS Biologicals, Littleton, CO, United States),
GFAP (Sigma-Aldrich, St. Louis, MO, United States), tau
pS202 (CP13; gift from Peter Davies, Albert Einstein College,
New York), caspase-cleaved actin (fractin from author Greg
Cole, Yang et al., 1998), platelet-endothelial cell adhesion
molecule-1 (PECAM-1), Synaptosome Associated Protein 25
(SNAP25), synaptophysin, drebrin and N-methyl D-aspartate
receptor subtype 2B (NMDAR2B or NR2B), NR2B (Santa Cruz
Biotechnology) then incubated with horseradish peroxidase-
conjugated secondary antibodies. SuperSignal West Femto
Substrate (Pierce, Rockford, IL, United States) was exposed
on x-ray film below saturation, and bands were scanned and
quantified using a UVP bio-imaging system (UVP, Upland, CA,
United States).
Mitochondrial Complexes
Mitochondrial enzymes were measured by western blot, using the
premixed cocktail of primary monoclonal antibodies provided
in the OxPhos Panel kit (Abcam, previously MitoSciences)
ab110413) against Complex I subunit NDUFB8 (ab110242),
CII complex II-30kDa (ab14714), Complex III-Core protein 2
(ab14745) Complex IV subunit I (ab14705) and Complex 5V
alpha subunit (ab14748). The lysis fraction from the hippocampal
extract was used, and samples loaded as described above.
Plasma Exosomes
Plasma was collected at euthanasia, prior to perfusion and
stored at −80◦C. Plasma exosomes were isolated according to
the method of exosome precipitation (Fiandaca et al., 2015).
Briefly, 250 µl of plasma was spun at 3000 × g for 15 min
then the supernatant with added protease inhibitor cocktail
(Roche Applied Sciences, Inc.) was incubated with 100 µl
thromboplastin-D (Thermo Scientific, Inc.) at room temperature
for 60 min. After spinning at 13,500 rpm for 5 min, the
supernatant with added protease inhibitor cocktail was mixed
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with 63 µl of ExoQuickTM-TC exosome precipitation solution
(System Biosciences, Inc.) and incubated at 4◦C for 60 min.
The samples were again spun at 1500 × g for 30 min, were
then removed and the supernatant was spun again for 5 min.
The pellets were re-suspended in 1 × PBS with H2O/protein
inhibitor. Then the isolated exosomes were purified by Exo-
spinTM column (Cell Guidance Systems, Inc.) according to the
manufacturer’s instructions. After purification, exosomes were
run on reduced 6–15% Tris-Glycine/SDS gel and western blot
was run using an anti-Aqp-4 (Novus Biologicals, Littleton, CO,
United States) antibody.
Statistical Analysis
Western and Mitochondrial Analysis
Statistical analysis was performed using SPSS V.22 (IBM, Inc).
Two way ANOVA [SHR (WKY or SHRSP) × FAD (Tg- or
Tg+)] was performed to determine differences in protein levels,
and where applicable, Multivariate Analysis (MANOVA) was
performed. Log or square root transformation for data with
unequal variances. Two-way ANOVA followed by post hoc LSD
or t-tests was used to analyze behavioral data. P-values lower than
0.05 were considered statistically significant. P-values between 0.1
and 0.05 were considered trends.
Immunohistochemical Analysis
Data for immunohistochemistry analysis were collected from
microscopic images acquired using a Macintosh computer with
a digital MC170 5 MPixel Leica camera on an Olympus
Vannox-T (AHBT) microscope. Images were then analyzed
using the public domain software Image J, http://rsbweb.nih.
gov/ij/. Immunohistochemical data were analyzed quantitatively
using two-way ANOVA (FAD × SHRSP × brain region),
and differences between strains were determined by Fisher’s
least significant difference (LSD) post hoc analysis. Sex was
included in the model only if initial analysis showed significant
effects (p < 0.05). A sex effect was identified only for Aqp-
4 western blot, as females showed the highest Aqp-4 increases
in SHRSP/FAD. Four consecutive sections and the bregma
specific for the region of interest were assessed per rat. Density
thresholding was used with Image J macros to evaluate integrative
density, size of individual cells number of cells per area, and
percentage area stained.
RESULTS
SHRSP/FAD Rats Show Hypertension
and Preservation of the SHRSP
Phenotype
Blood pressure readings were acquired from the
caudal tail arteries of the four strains (Figure 1). Data
were analyzed via MANOVA [variables (diastolic and
systolic) × SHRSP × FAD × sex], and log transformation
of data was needed to establish equal variance. The multivariate
main effect was only significant for SHRSP [Pillai’s Trace = 0.719,
F(4,50), p < 0.0001] as was the univariate main effect for
FIGURE 1 | Systolic and diastolic blood pressure is elevated in SHRSP and
SHRSP/FAD rats. Shown are systolic (red) and diastolic (blue) blood pressure
measurements in FAD (n = 11), SHRSP (n = 10), and SHRSP/FAD (n = 9) rats,
as well as non-transgenic WKY controls (n = 8), as measured in the rats’
caudal tail artery. The multivariate analysis showed a significant effect of
SHRSP only (p < 0.0001), indicating that SHRSP but not sex or FAD
transgene influenced blood pressure. Similarly the univariate F tests showed
significant main effects of SHRSP on both diastolic and systolic pressure
(p < 0.0001 and p < 0.0001, respectively). The univariate effect of FAD on
diastolic and systolic pressure was significant (p < 0.019, respectively), but
post hoc analysis showed that the trend for slightly higher pressure in
SHRSP/FAD rats was marginal and not significant. Post hoc analysis showed
that both systolic and diastolic pressure were higher in SHRSP and
SHRSP/FAD rats than in WKY and FAD (p < 0.001), consistent with
preservation of the SHRSP hypertensive phenotype in the SHRSP/FAD rat.
Data represent means ± SEM. ∗∗∗p < 0.001; MANOVA with Pillai’s Trace. Log
transformation of data was performed to establish homogeneity of variance.
SHRSP, on diastolic and systolic pressure [F(2,33) = 11.565,
p < 0.0001 and F(2,33) = 21.044, p < 0.0001, respectively].
Although univariate tests revealed a main effect of FAD,
post hoc analysis showed only incremental (5%) non-significant
increases in blood pressure in FAD rats, compared to WKY.
In contrast, post hoc analysis showed that both systolic and
diastolic pressures were higher in SHRSP and SHRSP/FAD rats,
compared to FAD and WKY rats (p < 0.001), consistent with
preservation of the SHRSP hypertensive phenotype in this new
SHRSP/FAD model.
Amyloid and Tau Pathology in the
Hippocampus
Amyloid-β Plaque Burden in SHRSP/FAD Is Slightly
Reduced and Plaques Have More Diffuse
Morphology Than in FAD Rats
Micrographs in Figure 2 depict Aβ deposition (6E10) in the
hippocampus of FAD and SHRSP/FAD rats, while no plaques
were observed in WKY rats. Quantitative analysis of plaque
number and percentage area stained was assessed in three brain
regions, the hilus (highest density of plaques), perirhinal and
entorhinal cortices (moderate plaque burden). Two-way ANOVA
was performed (strain × region) and log transformation was
used to obtain equal variances for percentage area stained. The
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FIGURE 2 | Neuritic Amyloid-β plaques in FAD rats become more diffuse with hypertension. Micrographs depicting Aβ (6E10) immunohistochemical staining of brain
sections (hippocampus) from FAD (n = 11) and SHRSP/FAD (n = 9) rats are shown. No plaques were observed in WKY rats, while there was sparse vascular staining
in the SHRSP rat (black arrow), unlike advance plaque pathology in the FAD and SHRSP/FAD groups. With the low magnification micrographs, more compact,
neuritic plaques (black arrows) were observed in FAD rats, whereas plaques in the hippocampus of SHRSP/FAD rats rarely had compact cores and were more
diffuse (blue arrows) and frequently associated with vessels (red asterisks). The highly vascularized hippocampal fissure is outlined in red. Although there was
moderate staining for Aβ in the HF of FAD rats, the SHRSP/FAD rats showed extensive staining of plaques and vessels (red asterisks). Since there was negligible
staining in the SHRSP and WKY groups, quantitative analysis was performed in the plaque-rich hilus, measuring Aβ plaque number and average percentage area
only in the FAD and SHRSP/FAD groups. Two-way ANOVA (region × strain) of percent area and count, showed significant region effects, which post hoc analysis
revealed was due to higher plaque burden and count in the hilus. For percent area, there was also a significant main effect of strain and post hoc analysis showed
that this was due to a reduction in plaques in the entorhinal cortex of SHRSP rats. For plaque count, two-way ANOVA showed an interaction between strain and
region. Post hoc analysis showed significant reductions in plaque number in both the entorhinal and perirhinal cortices of SHRSP rats. Data represent
means ± SEM. ∗p < 0.05, ∗∗p < 0.01; two-way ANOVA. Log transformation of data for percent area was also performed to establish homogeneity of variance.
main effects for strain and region were significant (p = 0.006
and p = 0.011, respectively) and while there was no interaction
between strain and region, post hoc analysis revealed a reduction
in plaque numbers in the entorhinal cortex of SHRSP/FAD rats
compared to FAD in (p = 0.001). Two-way ANOVA of plaque
number showed that the effects of strain or region were non-
significant, but there was a significant interaction between strain
and region (p = 0.002).
Post hoc analysis revealed that Aβ plaque number was
significantly reduced in the entorhinal and perirhinal cortices
of SHRSP/FAD rats (p < 0.05), whereas plaque number was
increased, albeit non-significantly (p = 0.07), in the hilus of
SHRSP/FAD rats, compared with FAD. Furthermore, plaques in
the SHRSP/FAD rats were more diffuse, when compared with
those in FAD rats, which were of coarser texture, typical of
neuritic plaques.
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Tau (pS422) Staining of Neurites and Cell Bodies and
Insoluble Tau (CP13) Levels Are Increased in
SHRSP/FAD Rats
In Figure 3, micrographs depict Tau pS422 staining in the
hippocampal hilus of the four strains. Unlike WKY, SHRSP and
FAD rats, which showed light staining of their hilar neurons,
SHRSP/FAD rats showed intense staining of occasional neurons
with pre-tangle morphology, similar to globose neurofibrillary
tangles, and a few displaying tortuous neurites. Two-way
ANOVA analysis of both percentage area stained and cell size,
showed significant main effects of SHRSP (p = 0.001 and
p = 0.006), FAD (p < 0.0001 and p < 0.0001) and SHRSP× FAD
interactions (p = 0.025 and p = 0.034). For percentage area
stained, the SHRSP/FAD rats showed two-fold increases in levels
above all other strains (p < 0.0001), which contributed to the
interaction between SHRSP and FAD. Despite the significant
main effect of FAD on percentage area of tau pS422 staining
and incremental increases in FAD and SHRSP rats, compared to
WKY, these differences were not significant with post hoc analysis.
In contrast, post hoc analysis showed that tau pS422-positive cell
size was significantly elevated in FAD rats, compared to WKY
(p< 0.01) and in SHRSP/FAD rats, compared to FAD (p< 0.001)
and SHRSP rats (p < 0.001). Together, this suggests that tau
pS422 staining is robustly increased in the hilus of SHRSP/FAD
rats, compared to FAD or SHRSP alone.
The lower right panel of Figure 3 shows representative lanes
from western blot experiments measuring tau protein (CP13
antibody) in the detergent lysis buffer insoluble pellets extracted
with SDS from hippocampi from the four rat strains. Two-way
ANOVA showed significant main effects for FAD effects and
the FAD × SHRSP interaction. Post hoc analysis showed a non-
significant trend for increased detergent insoluble CP13 levels
in FAD, compared to WKY rats. Whereas levels of CP13 in the
hippocampus were significantly elevated in SHRSP/FAD rats,
compared to WKY (p < 0.001), FAD (p < 0.05), and SHRSP
rats (p < 0.001). These data suggest that the small increase of
insoluble tau levels in the hippocampus of FAD rats is robustly
increased in the SHRSP/FAD rat.
Neuroinflammation
Iba1
Illustrated in Figure 4 are micrographs showing microglial
staining in the hilus of the hippocampus of the four strains.
Brains of WKY, FAD and SHRSP rats displayed microglia with
reactive ramified processes and well-defined, darkly stained oval
soma, which was most pronounced in SHRSP rats (red asterisks).
In contrast, in the SHRSP/FAD group, microglia were hyper-
ramified with thickened bushy processes (red dashed arrows)
and narrowed soma, some with occasional rod morphology
(black arrows). Total percentage area stained, cell size (soma
and branches) and cells per unit area were evaluated using
two-way ANOVA (FAD × SHRSP). There were no significant
FAD effects on Iba1-positive cell size or count, but there was a
main FAD effect (p < 0.0001) on percentage area stained and
a significant SHRSP × FAD interaction (p = 0.001). Post hoc
analysis showed that the significant SHRSP × FAD interaction
was related to an elevation of percentage area of Iba1 staining
in the hippocampus of SHRSP/FAD rats, compared to all the
other groups (p < 0.001). In fact, this significant interaction
was also seen with cell count and size, which post hoc analysis
revealed was similarly due to changes in the SHRSP/FAD rats
but not the FAD group. Post hoc analysis also demonstrated a
small FAD effect associated with increased microglia in FAD
rats (p < 0.05), but in SHRSP/FAD rats, the FAD effect was
associated with fewer microglia (p < 0.001), despite increased
percentage area stained.
Hypertrophic Astrocytes and Disorganized
Aquaporin-4+ End-Feet in SHRSP/FAD Rats
Figure 5 shows immunostaining of brain sections for the
astrocytic antigen GFAP. In Tg- WKY control rats, soma
generally extended thick primary branches, from which multiple
secondary and tertiary processes diverged. There are many
star-shaped soma typical of quiescent astrocytes. The most
noticeable difference between strains was increased GFAP
staining throughout the hilus and other regions of the brain (not
shown) in SHRSP/FAD rats. These SHRSP/FAD rats manifested
hypertrophied soma size, and extended thickened and dense
processes with fewer thin, secondary and tertiary processes,
consistent with immune activation. There was also a similar but
more modest effect in FAD rats as well as an SHRSP effect.
Specifically, astrocytes in the SHRSP rats had fewer processes
but more cells than WKY, consistent with SHRSP-dependent
proliferation. Data collected from image analysis were analyzed
by two-way ANOVA (region × SHRSP × FAD), which revealed
significant main effects. Data from square root transformation
of percentage area stained was used for ANOVA to establish
equal variance. There was a significant main effect of the FAD
transgene on percentage area stained, cell size and GFAP staining
intensity (p < 0.0001). Post hoc analysis indicated that while the
trends for increased percentage area of GFAP staining (p = 0.057)
and cell size (p = 0.066) in FAD, compared to WKY did not
reach significance, percentage area stained (p < 0.001) and
cell size (p < 0.0001) were robustly and significantly elevated
in the hippocampal hilus of SHRSP/FAD rats, compared to
WKY. Additionally, staining intensity was significantly elevated
in SHRSP/FAD rats, compared to FAD (p< 0.006). Furthermore,
post hoc analysis showed that percentage area (p = 0.005)
and cell size (p < 0.001) were elevated in the dentate gyrus
of SHRSP/FAD rats, compared to SHRSP. There were no
SHRSP interactions, only a main SHRSP effect on cell size
(p = 0.024), corresponding to a significant reduction of cell
size in SHRSP, compared to FAD rats (p < 0.05). Percentage
area stained, cell size and GFAP staining intensity all showed
a strong region effect (p < 0.0001) corresponding to more
robust increases in the plaque-enriched hilus of FAD and
SHRSP/FAD rats.
GFAP Protein Levels in the Entorhinal Cortex and
Hippocampus Are Increased in SHRSP/FAD Rats
The bottom panel of Figure 5 depicts representative lanes
of western blots for GFAP in two brain regions and the
densitometric analysis of bands normalized to actin. Consistent
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FIGURE 3 | Tau staining and insoluble protein levels are increased in SHRSP/FAD rats. Micrographs depict positive tau pS422 staining in the hilus of the
hippocampus of WKY (n = 8), FAD (n = 11), SHRSP (n = 10), and SHRSP/FAD (n = 9) rats. Only SHRSP/FAD rats showed intense staining of neurons labeling
globose neurofibrillary tangle-like structures extending tortuous neurites. Two-way ANOVA of percent area and cell size showed significant main effects of SHRSP
(p = 0.001, p = 0.006), FAD (p = 0.0001, p = 0.0001) and SHRSP × FAD interactions (p = 0.025, p = 0.034), respectively. Percentage area stained positive for tau
pS422 was increased more than two-fold in the SHRSP/FAD rats, compared to WKY, FAD and SHRSP rats (p < 0.0001). Post hoc analysis indicated that cell size
was significantly elevated in the hilus of FAD rats, compared to WKY (p < 0.01), while further elevations of tau pS422 cell size were detected in SHRSP/FAD rats,
compared to FAD and SHRSP rats (p < 0.001). The lower right panel shows representative lanes from a western blot analysis of CP13, an antibody to the serine
202 phospho-epitope of tau from the insoluble SDS fractions of hippocampal lysates. Two-way ANOVA showed a significant FAD effect and a FAD × SHR
interaction. Post hoc analysis showed that there was a non-significant trend for increased CP13 levels in hippocampus from FAD compared to WKY rats (p = 0.08).
However, in SHRSP/FAD rats, levels were significantly elevated compared to SHRSP rats (p < 0.001). Furthermore, CP13 levels were significantly elevated in the
hippocampus of SHRSP/FAD rats, compared to FAD (p < 0.05). Data represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; two-way ANOVA with LSD
Fisher’s post hoc test.
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FIGURE 4 | Microglial staining and cell size are increased in SHRSP/FAD rats. Micrographs show Iba1-positive microglia in the hippocampus of the four strains.
Microglia in SHRSP, FAD and WKY rats all showed normal ramified morphology with well-defined soma, which was more pronounced in the SHRSP rats (red
asterisks). In contrast, microglia in the SHRSP/FAD rat showed hyper-ramified, thickened bushy processes (red arrows) and narrowed soma, some with rod
morphology (black arrows). Two-way ANOVA (FAD × SHRSP) and showed a main FAD effect in percent area (p < 0.0001) and a significant SHRSP × FAD
interaction (p = 0.001). Post hoc analysis showed that percent area stained for Iba1 was elevated in the hippocampus of SHRSP/FAD rats, compared to all other
groups (p < 0.001). In fact this interaction was also seen with cell number and cell size, which post hoc analysis revealed was similarly due to significantly increased
Iba1-positive cell number in SHRSP/FAD rats, compared to all other groups combined (p = 0.005). Number of microglia was significantly increased in FAD rats,
compared to WKY, whereas cell count was significantly reduced in SHRSP/FAD rats, compared to SHRSP, despite increased area, associated with processes in
SHRSP/FAD animals. Data represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001; two-way ANOVA with LSD Fisher’s post hoc test.
with observations by IHC, one-way ANOVA showed that
there was a main effect of strain (p < 0.001). Post hoc
analysis showed that levels of GFAP were significantly
elevated in the lysis fraction from the entorhinal cortex and
hippocampus of FAD rats, compared with WKY. However,
in SHRSP/FAD rats, levels in both the entorhinal cortex and
hippocampus were higher than in all other groups. Together,
these data are consistent with multiple brain regions showing
increased astrogliosis in FAD rats, which is exacerbated in
SHRSP/FAD animals.
Aquaporin-4 Staining of Astrocyte End-Feet in the
Hippocampus Indicates Disruption of Morphology in
SHRSP/FAD Rats Along With Overall Increased Level
of Staining
Figure 6 shows staining forAqp-4, a membrane-bound protein in
astrocyte end-feet on vessels that regulates water permeability. In
WKY rats, Aqp-4 staining was associated with evenly distributed
small tubular vessels (black arrows), while in FAD rats, there were
patches of staining of vessels that appeared to be fragmented,
tortuous and thin astrocyte processes (red arrows) and swollen
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FIGURE 5 | Astrogliosis is augmented in SHRSP/FAD rats. (A) Micrographs show immunostaining of brain sections for the astrocytic antigen GFAP. In WKY rats,
soma generally extended thick primary branches (red arrowheads), from which multiple secondary and tertiary processes (blue arrowheads) diverged with
star-shaped soma typical (red asterisks) of quiescent astrocytes. There was increased GFAP staining throughout the hilus (similar to other regions, not shown) in
SHRSP/FAD rats, manifested by hypertrophied soma (yellow arrows) and extended thickened and dense processes (thick light blue arrows) with fewer thin,
secondary and tertiary processes, consistent with an activated state. (B) Quantitative image analysis showed that, percentage area of GFAP staining was
(Continued)
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FIGURE 5 | Continued
significantly elevated in SHRSP (p = 0.057) and SHRSP/FAD (p = 0.001) rats when compared with WKY, and in SHRSP/FAD rats when compared with FAD
(p = 0.005). Two-way ANOVA (region × SHRSP × FAD) revealed significant main effects for all variables (p < 0.0001), due to a robust increase in GFAP staining in
the hilus of FAD rats relative to plaque-sparse regions. GFAP staining intensity was increased further in the hilus of SHRSP/FAD rats (p < 0.006). In SHRSP/FAD rats,
however, all variables, including cell size, percentage area stained and GFAP staining intensity, were significantly elevated, compared to WKY and SHRSP rats.
(C) The lower two panels show representative western blot gels from experiments measuring GFAP protein in the lysis fraction of tissue lysates from the entorhinal
cortex and hippocampus. One-way ANOVA showed a significant effect of strain on GFAP protein levels in the entorhinal cortex (p = 0.006) and hippocampus
(p = 0.0015) and post hoc analysis indicated that GFAP protein levels were significantly elevated in entorhinal cortex and hippocampal tissue from SHRSP/FAD rats,
compared to all other groups. GFAP was also significantly elevated in the hippocampus of FAD rats, compared to WKY. Data represent means ± SEM. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001
vessels (blue asterisks). In SHRSP rats, there was an increase in
staining of slightly distended but normally shaped tubular vessels
(black arrows), compared to WKY.
The FAD-dependent increase in amorphous patches was
exacerbated in SHRSP/FAD rats (red arrows). Two-way ANOVA
showed no significant interaction of FAD × SHRSP effects for
count and percentage area stained. Post hoc analysis showed that
compared to FAD, there were more Aqp-4 puncta (p< 0.01) and
higher percentage area stained (p < 0.01) in the hippocampus
of SHRSP/FAD rats.
Aquaporin-4 Protein Levels Are Increased in the
Hippocampus of FAD Rats
Lysates were prepared from hippocampal tissue, and levels of
Aqp-4 were measured. Representative lanes of blots are shown in
Figure 6B (right, mid panel). Since Aqp-4 is prone to multimeric
aggregation, we used only 1 microgram of protein and did not
boil the sample buffer. Three main bands were identified: 37, 50,
and 150 kDa. Data from densitometric analysis were analyzed
by two-way ANOVA (FAD × SHRSP × sex), which indicated a
significant main effect of FAD on the 150 kDa Aqp-4 band. Post
hoc analysis showed that total Aqp-4 was significantly elevated
in FAD (p < 0.01) and SHRSP/FAD (p < 0.01), compared to
WKY and SHRSP rats, respectively. There was also a sex effect,
which post hoc analysis showed was due to higher Aqp-4 levels
in females across groups. However, there were no differences
between strains with sex. In conjunction with Aqp-4, GFAP was
measured in the same blot after re-probing, and was found to
positively correlate with levels of total (r2 = 0.379, p = 0.0003) or
monomeric Aqp-4 (r2 = 0.216, p = 0.0097).
Aquaporin-4 Levels in Plasma Exosomes
Plasma exosomes were analyzed for Aqp-4 by western blot
and relative optical density of the main band (150 kDa), was
calculated (Figure 6C). The only significant effect observed in the
two-way ANOVA was an interaction between FAD and SHRSP,
which post hoc analysis showed was due to a robust increase in
Aqp-4 in SHRSP/FAD rats that was higher than levels in FAD
and SHRSP rats (p< 0.05).
Collagen IV and PECAM-1 Are Elevated
in Brains of SHRSP/FAD Rats
Collagen IV Immunohistochemistry
Figure 7 depicts collagen IV staining in the brains of the four
strains, specifically the stratum lucidum of the hippocampus and
the globus pallidus of the basal ganglia. In all brain regions
of WKY rats, vessels were lightly stained with no collagen IV
staining in the vessel lumen. However, the lumen of capillaries
in SHRSP rats showed sparse collagen IV immunoreactivity.
Within the globus pallidus, a noticeable increase in collagen IV
staining in FAD rats was observed, which was further increased
in SHRSP/FAD rats, where vessel walls appeared distorted and
thickened. Two-way ANOVA of percentage area of collagen IV
staining was performed (region × FAD × SHRSP) (Figure 7B).
Main SHRSP (p < 0.0001) and FAD (p < 0.003) effects on
percentage area stained for collagen IV were significant as
for region (p = 0.003) and the interaction between region
and FAD (p = 0.028), likely reflecting regional differences in
the percentage area stained for collagen IV (the hindlimb of
somatosensory cortex showed the least staining) and the more
pronounced group effects in the globus pallidus. The hindlimb
of somatosensory 1 was minimally affected: compared to WKY
rats, only the percentage area of collagen IV staining was
significantly increased in SHRSP (p < 0.05). In the hippocampus
(stratum lucidum), the SHRSP/FAD group showed the highest
percentage area stained (p < 0.05). In contrast to these
modest effects, there were several group differences within the
globus pallidus. Compared to WKY, collagen IV staining was
significantly elevated in FAD (p < 0.001) and SHRSP (p < 0.05)
and SHRSP/FAD (p < 0.0001) groups, and percentage area
stained was higher in the SHRSP/FAD group than in all other
groups (p< 0.0001).
PECAM-1 (CD31) Is Elevated in Brains of SHRSP/FAD
Rats
By western blot, we assessed changes in the endothelial cell
tight junction marker PECAM-1 in the cytoskeletal/lysis fraction,
to where PECAM-1 is redistributed in response to chronic
neuroinflammation and associated with disruption of the BBB
(Romer et al., 1995; Ferrero et al., 1996). We measured PECAM-1
by western blot in the lysis fraction from hippocampal tissue as a
biomarker of BBB leakage (Figure 7C). Representative gel blots
are shown in the lower panel (Figure 7C). Densitometric analysis
of bands was performed and one-way ANOVA demonstrated
a significant effect of strain on PECAM-1 levels. Post hoc
analysis showed that levels of PECAM-1 were significantly
elevated in the hippocampal lysis fraction from SHRSP/FAD
rats, compared with FAD and SHRSP groups combined
(p < 0.01). Furthermore, PECAM-1 protein was significantly
lower in hippocampal tissue from FAD rats, compared to
WKY (p< 0.05).
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FIGURE 6 | Continued
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FIGURE 6 | Aquaporin-4 is elevated in the brains of FAD, with a further increase in SHRSP/FAD rats, while aquaporin-4 protein levels in plasma exosomes were
elevated in SHRSP/FAD rats only. (A) Micrographs illustrate staining for Aqp-4, a membrane-bound protein in astrocyte end-feet. In WKY rats, staining was
associated with evenly distributed small tubular vessels (black arrows), while in FAD rats, staining was in patches of fragmented vessels, tortuous thin astrocyte
processes (red arrows) and swollen vessels (blue asterisks). In SHRSP rats, Aqp-4 staining was slightly increased and labeled distended but normally shaped tubular
vessels (black arrows). There were more Aqp-4-positive amorphous patches in the hippocampus of FAD rats, an effect that was exacerbated in SHRSP/FAD rats
(red arrows). Two-way ANOVA showed FAD (p < 0.0001) and SHRSP (p < 0.0001) effects for count and percent area. Post hoc analysis showed that in the
hippocampus, Aqp-4 count (p < 0.001) and percentage area stained (p < 0.001) were significantly elevated in FAD, compared to WKY rats. This effect was further
increased in SHRSP/FAD rats in which Aqp-4 count (p < 0.01) and percentage area stained (p < 0.01) were significantly increased, compared to FAD rats. In
SHRSP/FAD rats, there were more structures stained positively for Aqp-4 (p < 0.001) and a higher percentage area stained (p < 0.001), compared to SHRSP.
(B) Aqp-4 was also measured in hippocampal tissue lysates (mid right panel) and analyzed by two-way ANOVA (FAD × SHRSP × sex), which showed a significant
main effect of FAD on the 150 kDa Aqp-4. Post hoc analysis demonstrated that Aqp-4 (150 kDa) was significantly elevated in the hippocampal tissue from FAD,
compared to WKY and SHRSP rats (p < 0.01). (C) The 150 kDa Aqp-4 protein was also measured in brain-derived plasma exosomes (bottom panel) and two-way
ANOVA (FAD × SHRSP × sex) demonstrated a significant interaction between FAD and SHRSP. Post hoc analysis showed that Aqp-4 (150 kDa) was significantly
elevated in plasma exosomes from SHRSP/FAD rats, compared to FAD and SHRSP rats (p < 0.05). Data represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001.
Calbindin Staining Is Reduced Slightly in
SHRSP and Robustly in SHRSP/FAD
Rats, While Caspase-Cleaved Actin
Fractin Is Increased in SHRSP/FAD Rats
Calbindin Staining in the Thalamus and
Hypothalamus Is Reduced in SHRSP/FAD Rats
To examine neuron damage we stained sections for calbindin,
a neuroprotective calcium-binding peptide, which is
predominantly enriched in GABAergic neurons, and its
loss is associated with tangle pathology (Ahmadian et al., 2015).
Images shown in Figure 8A illustrate positive calbindin staining
in the reticular thalamus and the lateral hypothalamus. The
intensity of staining of calbindin-immunoreactive neurons was
variable across the strains, but the area stained was noticeably
reduced in the SHRSP/FAD group. Two-way ANOVA of
percentage area (SHRSP × FAD) in the thalamus showed
a significant main effect of SHRSP, and post hoc analysis
showed reduced calbindin levels in SHRSP (p < 0.05) and
SHRSP/FAD (p < 0.001) rats, compared to WKY (Figure 8B).
Furthermore, calbindin staining in the thalamus was significantly
reduced in SHRSP/FAD rats, compared to FAD (p < 0.01),
suggesting that calbindin-positive neuron loss in the thalamus
was exacerbated in SHRSP/FAD rats, compared to FAD rats
without hypertension. In the hypothalamus, there was a
significant main effect of FAD (p < 0.025), in addition to
a significant SHRSP effect (p < 0.0001). Post hoc analysis
showed that percentage area of calbindin staining was
significantly reduced in the hypothalamus of SHRSP/FAD
rats, when compared to all other groups (p < 0.01) rats
(Figure 8B). Together, these data support that the reduction of
calbindin staining in the brains of SHRSP rats is exacerbated in
SHRSP/FAD animals.
Levels of Most Synaptic Proteins Were Unchanged in
the Hippocampus, While NR2B and Caspase-Cleaved
Actin (Fractin) Were Elevated in SHRSP/FAD Rats
To further examine neurodegeneration, we measured synaptic
proteins in membrane-enriched fractins in western blots
(not shown). There were no changes in levels of pre-
synaptic proteins SNAP25 and synaptophysin, nor in levels
of the post-synaptic protein drebrin, however, levels of
post-synaptic NR2B were different among strains (Figure 8D).
Post hoc analysis showed that, although FAD showed a slight
elevation in NR2B levels compared to WKY, NR2B levels
were elevated in the SHRSP/FAD groups more than all other
groups (p< 0.01).
We also measured caspase-cleaved actin (fractin (Yang et al.,
1998), as an indicator of caspase-mediated apoptosis (Figure 8,
lower panel). One-way analysis of relative optical density (relOD)
of the bands showed a significant strain effect [F(3,16) = 4.2,
p = 0.045] and post hoc analysis showed that levels of caspase-
cleaved actin in the SHRSP/FAD rats were significantly higher
than in WKY rats (p< 0.05).
Luxol Fast Blue Staining Shows
Demyelination in White Matter Tracts in
SHRSP Which Is Exacerbated in
SHRSP/FAD Rats
Figure 9 depicts representative images of the retrosplenial cortex
and hippocampus of all strains stained with Luxol fast blue,
to visualize changes in myelin distribution between strains.
Qualitative evaluation by an experimenter blinded to transgene,
showed changes in myelin in both regions among the strains. In
the cortex and corpus callosum (CC) (top panel) of WKY rats,
there was extensive Luxol fast blue staining, which densely labeled
the CC and was evenly spread. However, in FAD rats there were
dark patches of Luxol fast blue, interspersed with white patches
of demyelination. In contrast to these minor changes in FAD
rats, there was notable loss of myelin patches in both SHRSP
groups in the CC and cortex. In the SHRSP/FAD rat occasional
lacunae appeared in the perirhinal cortex (not shown) and in the
cortex-CC interface surrounded by a halo of demyelination (top
right panel).
Selective layers of the hippocampus were affected differentially
in the four strains. There was no change in Luxol fast blue
in the stratum molecular among strains, but in the FAD and
SHRSP rats, there was some loss of myelin in the stratum
radiatum and lucidum reflected in irregular patches of blue in
the FAD rat brain, with more extensive loss in the SHRSP/FAD
rats. The most pronounced loss of myelin was seen in the
hippocampal fissure of the SHRSP/FAD rat, when compared with
all other strains.
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FIGURE 7 | Collagen IV deposition is increased in FAD and SHRSP rats, while PECAM-1 is increased in SHRSP/FAD rats only. (A) Micrographs depict collagen IV
staining in stratum lucidum of the hippocampus and globus pallidus of the basal ganglia. In all brain regions of WKY rats, vessels were lightly stained, and there was
no staining in the vessel lumen. However, in SHRSP rats, the lumen of capillaries showed sparse collagen IV immunoreactivity. There was increased staining in the
globus pallidus of FAD rats, which was exacerbated in SHRSP/FAD rats, in which vessel walls appeared distorted and thickened. (B) Two-way ANOVA was
performed [region (three brain regions) × FAD (Tg+ or Tg–) × SHRSP (non-SHRSP or WKY)].The main effects for both SHRSP were highly significant (p < 0.0001),
and the effects for FAD, the effects of region and the interaction between FAD and region were also significant (p = 0.003, p = 0.003, and p = 0.028 respectively).
Post hoc analysis with planned comparisons showed elevated intensity of collagen-IV staining in the hindlimb of SHRSP rats, compared to WKY (p < 0.05). In
stratum lucidum of the hippocampus, collagen-IV staining was significantly elevated in SHRSP/FAD rats, compared to WKY (p < 0.05). Collagen-IV staining was
(Continued)
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FIGURE 7 | Continued
increased significantly in the globus pallidus of FAD (p < 0.001) and SHRSP rats (p < 0.0001), compared to WKY. In SHRSP/FAD rats, collagen-IV staining was
significantly increased further compared to FAD (p < 0.001) and SHRSP (p < 0.01) rats. (C) We also measured endothelial cell marker PECAM-1 in the lysis fraction
of hippocampal tissue. Representative gel blots are shown and densitometry of bands was evaluated via one-way ANOVA, which demonstrated significant effects of
strain on PECAM-1 levels. Post hoc analysis showed that levels of PECAM-1 were significantly elevated in the hippocampal lysis fraction from SHRSP/FAD rats,
compared with FAD and SHRSP rats (p < 0.01). Levels of PECAM-1 were also significantly reduced in FAD rats, compared to WKY (p < 0.05). Data represent
means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Mitochondrial Complex I Is Reduced in
Brains of SHRSP/FAD and FAD Rats,
While Complex II Is Reduced in
SHRSP/FAD Rats Only
Figure 10 shows representative lanes of the western blot
of mitochondrial complexes I-V from hippocampal tissue.
MANOVA was performed on protein band relOD of
Complexes I (log transformation), and II -IV (Complexes
I-IV × SHRSP × FAD). Results showed a significant main FAD
effect [F(4,23) = 3.421, Wilks λ = 0.627, p = 0.025]. The univariate
test showed significant FAD main effects on Complexes I and II
(p< 0.0001 and p< 0.039, respectively), but not III or IV. Levels
of Complex I were significantly reduced in FAD (p < 0.01) and
SHRSP/FAD (p < 0.01) rats, compared to WKY, while Complex
II was reduced three-fold in SHRSP/FAD rats only (p < 0.05).
These data suggest that mitochondrial Complex I is depleted in
the hippocampus of FAD rats only and Complex II is depleted
in the SHRSP/FAD.
SHRSP Does Not Exacerbate FAD
Deficits in Y Maze and Novel Object
Recognition but Has Independent Effect
on Hyperactivity
Novel Object Recognition Task
Two-way ANOVA (object preference × strain) demonstrated
a significant preference for the novel object during the test
phase of the NOR task in WKY rats (p < 0.001), however, in
FAD animals, the recognition index (RI) [(time exploring novel
object)/(time exploring both objects)] for the novel object did
not differ significantly from that of the familiar object (p > 0.05)
in any of the other strains, indicating a failure to recognize the
novel object as a result of impaired working memory in SHRSP,
FAD and SHRSP/FAD rats. Similar results were observed when
calculating a discrimination index (DI) [(novel time –familiar
time)/(novel time+ familiar time)].
It is noteworthy that distance (Figure 11A) and speed (not
shown) were significantly higher in SHRSP and SHRSP/FAD
animals during the NOR test phase, when compared with control
and FAD rats (Figure 11). Similar hyperactivity was evident
in SHRSP and SHRSP/FAD animals during the open field task
(OFT) (not shown). Collectively these data are consistent with
SHRSP not affecting preference for novel object with or without
FAD, but causing hyperactivity independent of FAD.
Y Maze
During an 8-min Y maze task, correct arm entries, speed, distance
(Figure 11B), spontaneous alternation, and errors (not shown)
were assessed. Two-way ANOVA (FAD × SHRSP) showed
significant main effects of FAD on correct arm entries, speed and
distance (p< 0.005), but no SHRSP effects or interactions.
Post hoc analysis showed a correct arm entries were
significantly lower in FAD rats compared to WKY (p = 0.0026),
and while there was also a reduction in correct arm entries in the
SHRSP/FAD rats, this difference did not reach significance. Post
hoc analysis also showed that SHRSP/FAD rats were significantly
slower in the Y maze than SHRSP rats (p = 0.0042), while a
slight reduction of speed in FAD rats, compared to WKY, was
not significant. Finally, FAD-dependent reductions in speed were
shown by post hoc analysis, whereby FAD and SHRSP/FAD rats
were significantly slower in the Y maze, when compared with
WKY (p< 0.01) and SHRSP (p< 0.001) rats, respectively.
DISCUSSION
Here we present an initial characterization of a novel rat
model of MxD, exhibiting complex interactions between
chronic hypertension and AD pathology. Crossing the SHRSP
background into the FAD rats (SHRSP/FAD) produces a line that
retains both the AD phenotype with extensive plaque pathology
as well as the SHRSP hypertensive phenotype. Importantly to
facilitate the investigation of direct effects of hypertension on
AD dementia, we created a FAD+ control line, by introducing
WKY background (non-hypertensive background strain for the
SHRSP), which retained the FAD transgene-dependent neuritic
plaque phenotype and behavioral deficits of the original F344 line.
Our data show region-dependent synergistic interactions,
with exacerbated metabolic deficits, demyelination, gliosis, tau
pathology and neurodegeneration in SHRSP/FAD rats, which is
consistent with clinical and neuropathological data suggesting
that coexistence of subclinical AD and SVD pathologies may
lower the threshold for dementia risk (Fischer et al., 1991).
We also observed exacerbation of SHRSP-dependent vascular
changes in SHRSP/FAD rats, indicative of leakage and disruption
of the BBB, but without greatly exacerbating AD plaque burden,
consistent with the clinical neuropathological data on neuritic
plaques in MxD (Petrovitch et al., 2005). This novel model
should allow a better understanding of how hypertension may
differentially affect neuritic and diffuse plaque and vascular
amyloid pathology. It may provide a useful model for translation
to identify how hypertensive phenotypes may interfere with the
efficacy of some AD therapeutics, possibly even when vascular
or AD pathological markers are below levels of detectability
with standard neuroimaging (Fischer et al., 1991; Baker et al.,
2012). This type of model is critical as undetected vascular
damage could limit the efficacy of drugs that target AD pathology
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FIGURE 8 | Neuron-specific calbindin is reduced in SHRSP/FAD rats, while caspase-cleaved actin is increased. (A) Micrographs depict calbindin staining in the
hypothalamus and thalamus showing numerous calbindin-immunoreactive neurons. (B) Two-way ANOVA of percentage area stained (SHRSP × FAD) in the reticular
thalamus showed no effect of sex, but a significant main effect of SHRSP (p < 0.0001), consistent with post hoc analysis, which showed that calbindin staining was
reduced in SHRSP (p < 0.05) and SHRSP/FAD (p < 0.001) rats, compared to WKY. Furthermore, calbindin staining was significantly reduced in SHRSP/FAD rats,
compared to FAD (p < 0.01), suggesting that FAD exacerbates neuron loss in SHRSP rats. Changes in calbindin staining in the hypothalamus were similar, and while
there was a main SHRSP effect (p < 0.0001), there was an additional FAD main effect (p < 0.025). Post hoc analysis showed that calbindin staining was significantly
reduced in the hypothalamus of SHRSP/FAD rats, compared to SHRSP (p < 0.0001), FAD (p < 0.01), and WKY (p < 0.0001) rats. (C) We also measured
caspase-cleaved actin in the entorhinal cortex as an indication of caspase activity by western blot (lower panel). One-way ANOVA of relative optical density showed a
significant strain effect (p = 0.045), and post hoc analysis showed that levels of caspase-cleaved actin were increased in SHRSP/FAD rats compared to WKY rats
(p < 0.05). (D) Levels of post-synaptic NR2B were significantly different among strains. There were main effects of strain, and post hoc analysis showed a slight
elevation of NR2B levels in FAD compared to WKY, but levels in SHRSP/FAD groups were higher than all other groups (p < 0.01).Data represent means ± SEM.
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; one- and two-way ANOVA with LSD Fisher’s post hoc test.
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FIGURE 9 | Demyelination in the cortex, corpus callosum and the hippocampal fissure of SHRSP/FAD rats. Sections were stained with Luxol fast blue to visualize
changes in myelin distribution between the different strains. Qualitative evaluation by a blinded experimenter showed changes in myelin in both regions among the
strains. Top panels show extensive, evenly spread Luxol fast blue staining, which densely labeled the corpus callosum (CC) of WKY rats. However, in FAD rats, there
were dark patches of Luxol fast blue, interspersed with white patches of demyelination. In contrast to these minor changes in FAD rats, there was a notable loss of
myelin patches in the CC and cortex of SHRSP and SHRSP/FAD groups. The top right panel shows a lacuna in the cortex-CC interface surrounded by a halo of
demyelination (red arrow). There was no change in Luxol fast blue in the stratum molecular (SM) among strains, but in the FAD and SHRSP rats, there was some loss
of myelin in the stratum radiatum (SR) and lucidum (SL) reflected by irregular patches of blue in the FAD rat, with more extensive loss in the SHRSP/FAD rats. The
most pronounced loss of myelin was seen in the hippocampal fissure of SHRSP/FAD rats.
FIGURE 10 | Mitochondrial complex II is reduced in the hippocampus of SHRSP/FAD rats and mitochondrial complex I is reduced in FAD rats. We measured
mitochondrial complexes I-IV from hippocampal tissue by western blot and MANOVA was performed on the relative optical densities of protein bands from
complexes I (log transformation), and II-IV. Results showed no sex effects, but a significant main FAD effect (p = 0.025) and the univariate test showed significant
FAD main effects for Complexes I and II (p < 0.0001 and p < 0.039, respectively), but not III and IV. Although complex I proteins were significantly reduced in
SHRSP/FAD (p < 0.01) and FAD (p < 0.01) rats, compared to WKY, complex II levels, were significantly reduced more than threefold in SHRSP/FAD rats, compared
to WKY (p < 0.05). Data represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01; MANOVA with Wilks λ test and LSD Fisher’s post hoc test.
alone. Moreover, this model may be useful for preclinical
research aimed at delineating the pathophysiology of VaD and
MxD and development of therapies for patients with MxD,
in which the causes of cognitive decline are complex and
therapeutic efficacy and safety may be limited by coexisting
pathologies in MxD or VaD.
Subtle Changes in Plaque Pathology in
the SHRSP/FAD Rat
SHRSP did not have an overwhelming impact on overall
plaque burden in the FAD rats, as it slightly reduced Aβ
staining in entorhinal and perirhinal cortices of SHRSP/FAD
rats, increased Aβ in the hilus and vessel-rich hippocampal
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FIGURE 11 | Performance in the novel object recognition and Y maze tasks by WKY, FAD, SHRSP and SHRSP/FAD rats. Data were analyzed by two-way ANOVA
(FAD × SHRSP). (A) The novel object recognition (NOR) task involved 2 days of habituation, followed by exposure of the rats to two identical objects in an
acquisition phase, prior to a test phase, following a retention period of 1 h. Graphs depict recognition indices (RI; time exploring novel or familiar object/time
exploring both objects × 100) and discrimination index [DI; (time exploring novel object – familiar object)/(time exploring novel object + familiar object)] in the test
phase of the NOR task in FAD (n = 11), SHRSP (n = 10), SHRSP/FAD (n = 9) and non-transgenic (n = 8) rats. Two-way ANOVA showed no sex effect, but there was
an interaction between strain and object preference (p < 0.05) and object preference (p = 0.0089). Fisher’s LSD post hoc comparisons indicated that only WKY
controls showed a significant preference for the novel object (p < 0.05). Similar results were seen with the two-way ANOVA with DI. Similarly, although two-way
ANOVA showed that variation of the DI among groups in the test phase of the NOR task was not significant, t-tests within groups showed that the NOR test phase
DI was significantly lower in FAD rats, compared to WKY (p = 0.029). However, the trends for lower DI in SHRSP and SHRSP/FAD rats, when compared with WKY,
were non-significant. Two-way ANOVA of distance traveled during test phase of the NOR task showed a significant effect of SHRSP (p < 0.0001), and a trend for a
main effect for FAD (p = 0.06). Fisher’s LSD post hoc analysis showed that distance traveled in the SHRSP group was significantly higher than in WKY (p < 0.01).
Since there was no interaction, the near significance of FAD is attributed to similar reductions in distance, independent of SHRSP. (B) Performance in the Y maze is
shown for FAD, SHRSP, SHRSP/FAD and WKY rats. No differences in spontaneous alternation were seen between strains (not shown). Correct arm entries were
assessed by two-way ANOVA showing no interaction between strain and FAD, although there was a significant FAD effect (p < 0.0026). Post hoc analysis revealed
that the number of correct arm entries was significantly lower in FAD rats only, compared to WKY (p < 0.05). Similarly there was a significant FAD effect on speed
(p < 0.0042) and distance (p < 0.0001) in the Y maze. Post hoc analysis showed that speed was significantly lower in SHRSP/FAD rats, compared to SHRSP, while
distance was reduced in FAD and SHRSP/FAD rats, compared to WKY (p < 0.01) and SHRSP (p < 0.001), respectively. Data represent means ± SEM. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA with Fisher’s LSD post hoc test.
fissure and altered plaque morphology, reducing the plaque’s
neuritic dense-core plaques decorating FAD brain. This is
contrast to the models with hypertension induced increases in
Aβ discussed in the introduction. Although we lack rigorous
clinical data describing differences in plaques between AD and
MxD, our data is consistent with findings in the Honolulu
Aging Study showing increased dementia risk developing in
cognitively normal men with vascular pathology who were
found to have increased tau pathology but fewer neuritic
amyloid plaques (Petrovitch et al., 2005). Together these data
support that, although hypertension exerts complex effects on
Aβ pathology, it does not accelerate plaque pathogenesis in our
model or in humans.
Whether or not hypertension attenuates the evolution of
the diffuse plaque into a dense neuritic plaque or directly
affects preexisting neuritic plaques, regional differences
in neuroinflammatory responses could explain this effect.
Compared to WKY, we observed relatively region-independent
increased neuroinflammatory responses in SHRSP. FAD rats had
much higher glial responses than SHRSP rats but this was region-
dependent and particularly high in plaque-rich regions like
the hilus, with disproportionate plaque burden, and less where
there were fewer plaques (entorhinal, perirhinal), consistent
with a strong inflammatory response to plaques. Therefore, the
regional variations in plaques in SHRSP/FAD could be related
regional glial responses to plaques, increasing or attenuating
clearance. It should also be investigated whether diminished
plaques could occur directly in response to hypertension
as in the mutant APP crossed onto db/db mice which have
hypertension and Type II diabetes and show a slight reduction
in plaques (Ramos-Rodriguez et al., 2015; Infante-Garcia
et al., 2016) or result secondary to enhanced clearance from
lacunar stroke and increased monocyte/macrophage invasion
(Frautschy et al., 1992).
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In addition to possible innate immune clearance mechanisms,
our model may impact LRP1 which mediates Aβ efflux
in cerebral microvessels (Donahue et al., 2006; Kanekiyo
et al., 2012) or receptor for advanced glycation end products
(RAGE) in neurons which can mediate Aβ influx (Deane
et al., 2003) or LDLR that can reduce Aβ (Kim et al.,
2009; Katsouri and Georgopoulos, 2011). Specifically it would
be important to examine redistribution of RAGE and LRP1
between microvasculature and neurons which appears Aβ or
AD specific (Donahue et al., 2006; Shang et al., 2019) and
increased expression of the low-density lipoprotein receptor
(LDLR) which appears hypertension or SHRSP-specific (Ueno
et al., 2010). However, whatever the mechanisms involved are,
the Aβ effects are surprisingly small and regional and not the
salient interactive feature in our model or in humans. The
mechanisms determining potentially regional changes in Aβ
clearance affecting plaque pathology include regional cerebral
hypoperfusion and are clearly complex and poorly understood.
Notably, two studies with surgically induced or angiotensin
II infusion-induced hypertension did not show hypertension-
associated amyloid reduction (Cifuentes et al., 2015; Shih et al.,
2018). Although those studies did not evaluate plaque burden
in the regions described here, they support our conclusions that
the impact on plaques is subtle and requires more thorough
examination of vascular amyloid and the relationship of vessels to
focal changes in cerebral blood flow, neuroinflammation, lacunar
or vascular changes, plaque size, texture and distribution in the
SHRSP/FAD rat and in patients with MxD.
One limitation of our study is that because amyloid effects
were small and regional, we did not pursue regional effects
of SHRSP on amyloidogenic APP processing or changes in
soluble oligomeric species. One might expect that there would
be synergism between effects of hypertension and AD on APP
processing, since hypertension models suggest that with aging
hypertension increases the activity of β-secretase (not mRNA)
as well as APP binding proteins (Csiszar et al., 2013; Zhang
et al., 2018, 2019) and in AD models, expression of β-site
amyloid precursor protein-cleaving enzyme 1 (BACE1) can be
upregulated by oxidative damage or inflammation (Zhang et al.,
2018). However, synergism between effects of hypertension and
AD on APP processing as a primary mechanism, is not supported
by the subtle differences in Aβ observed in our model and in
human MxD data.
Diffuse extracellular Aβ has been reported in brains of SHRSP
rats (Bueche et al., 2014; Schreiber et al., 2014) using anti-Rodent
Aβ antibody, which binds to the three rodent specific amino acid
differences present in Aβ 1-16, but also in full length APP and
its C-terminal fragment. Unfortunately, labeling with this class of
1–16 region antibody also detects APP and its non-Aβ products
associated with sites of axonal injury as well as Aβ. While we
used polyclonal anti human Aβ (Launer et al., 2000; Petrovitch
et al., 2000; Ferri et al., 2005; Petrovitch et al., 2005; Jellinger and
Attems, 2007; Kalaria et al., 2012; Hebert et al., 2013; Rodrigue
et al., 2013; Wimo et al., 2013; Gottesman et al., 2014; Oberlin
et al., 2015; Khan et al., 2016; Custodio et al., 2017; Walker et al.,
2017; Vinters et al., 2018; Wennberg et al., 2019) and showed
that SHRSP rats showed rare sparse vascular Aβ pathology and
rare diffuse plaques, our findings are still in agreement with
Schreiber’s group who found limited Aβ deposition or neuritic
plaques in SHRSP rats in contrast to the extensive deposition
observed in our FAD and SHRSP/FAD groups.
Robust Changes in Tau Pathology in the
SHRSP/FAD Rat
The F344 Tg AD rat, from which our model was derived
exhibits amyloid plaque pathology, insoluble tau and age-
dependent cognitive deterioration, but surprisingly insoluble tau
is reduced with age in the original report (Cohen et al., 2013).
However, the introduction of hypertension in SHRSP/FAD rats
robustly increased tau pathology. Importantly these data show
that low levels of vascular pathology caused by hypertension
may exacerbate tau pathology, despite minimal effects on
amyloid pathology. There has not been research directly
investigating hypertension and tau, however, there are two
reports that indirectly support our observations. First, APP
mice with the hypertensive db/db background show increased
phospho- tau levels (Ramos-Rodriguez et al., 2015; Infante-
Garcia et al., 2016), but increased Aβ and neuroinflammation
associated with diabetes in this model could have driven
tau hyperphosphorylation independent of hypertension. As
described above, cognitively normal men with hypertension,
who have fewer neuritic plaques but more tau pathology are at
increased risk for AD (Petrovitch et al., 2005). Thus, if validated
with further clinical and longitudinal neuropathological studies,
our initial finding that hypertension increases tau pathogenesis in
our MxD model would be an important advance in the field.
The Schreiber group reported that the SHRSP rat exhibits
tau hyperphosphorylation (Schreiber et al., 2014), however, no
evidence of unambiguous neurofibrillary tangles or detergent
insoluble tau was established. Because hyperphosphorylation
of tau is commonly observed with rodent brain injury and
inflammation in the absence of detergent insoluble tau or tangles,
findings of increased ptau by ICC or soluble ptau cannot be
conflated with insoluble aggregating tau or tangles but it may
indicate a relevant imbalance in tau kinases, phosphatases or
clearance mechanisms. While p-tau levels in the present study
were comparable between FAD and SHRSP rats, contrary to
(Schreiber et al., 2014), several differences exist between their
methods and ours. (1) the Schreiber laboratory used AT8 [to
both Tau pSer202 and pThr205 (Schreiber et al., 2014) while
we used pS422 and CP13 to Tau pSer422 and Tau pSer202,
respectively; (2) they did not used phosphatase inhibitors that
prevent post mortem phosphorylation, (3) they only used males
which have more hypertension; and (4) they evaluated the cortex
while we evaluated hippocampus. Nevertheless, our combined
results suggest chronic hypertension may promote tauopathy, a
known path to neurodegeneration.
Robust Increases in Microglial and
Astrocytic Neuroinflammation in the
SHRSP/FAD Rat
Similar to AD (Akiyama et al., 2000) and CBVD (Gallart-
Palau et al., 2017), there was increased microgliosis and
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hyperplasia of astrocytes in both FAD and SHRSP rats. Although
increased neuroinflammation has previously been reported in
both models (Sabbatini et al., 2002; Cohen et al., 2013; Tayebati
et al., 2016), this is the first observation showing an additive
response with the coexistence of robust AD pathology and
hypertension. Specifically, brains of SHRSP/FAD rats showed
increased glial density and percentage of positive staining.
Notably, average microglia and astrocyte cell size were further
elevated in the cross, indicative of reactive cells. Compared
with SHRSP rats, which are not reported to show hypertrophy
of astrocytes (Sabbatini et al., 2002; Tayebati et al., 2015),
astrocytes in brains of SHRSP/FAD rats were significantly larger.
Our data suggest that the combination of SHRSP phenotype
with the AD transgene in the SHRSP/FAD rat enhances
gliosis and possibly neuroinflammation generally in the brain
beyond that seen with either alone which suggests a synergistic
amplification of this pathology caused by the coexistence of
AD pathology and hypertension. Further examination of the
transcriptomic and functional profiles of glial cells in specific
regions of these animals will help to clarify the effect that
hypertension has on glial cells in the context of AD. Not
only was microgliosis increased in SHRSP/FAD rats, microglial
morphology was also different, compared with all other animals.
Many microglia in the brains of SHRSP/FAD rats were rod-
shaped and had more processes, such that there was more
total Iba1-positive area stained, despite fewer microglial cells.
Notably, several microglia had larger cell bodies, which typically
associated with microvessels. Previously in a mouse model
of stroke, it was found that microglia played a pathogenic
role surrounding and phagocytosing endothelial cells leading
to the disintegration of vessels, which was in part stimulated
by fibrinogen or albumin, both indices of vessel leakage
(Jolivel et al., 2015). While we did observe vessel-associated
microglia and the density of vessels associated with Aqp-
4 and collagen IV, we did not evaluate the density of all
vessels. However, dysregulated Aqp-4 staining, an astrocytic
endfoot protein that associates with cerebral blood vessels,
in the SHRSP/FAD rat is consistent with damage to the
neurovascular unit.
Aquaporin-4 in Microvessels in the
SHRSP/FAD Rat
Parallel to GFAP changes, the astrocytic endfoot protein Aqp-
4 was upregulated in the hippocampus of SHRSP/FAD rats.
It is known that Aqp-4 is increased in brains of SHRSP rats
(Tomassoni et al., 2010; Tayebati et al., 2015) and in AD brain,
in association with amyloid plaques (Hoshi et al., 2012; Yang
et al., 2017). Our data indicate that this upregulation of Aqp-
4 is amplified in the SHRSP/FAD rat. A positive correlation
between Aqp-4 and GFAP protein levels are consistent with
prior reports of increased Aqp-4 corresponding with increased
gliosis in a model of hypoglycemia (Zhao et al., 2018). Aqp-
4 staining was redistributed to the neuropil, but it was unclear
whether the loss of polarization was due to disintegration of
vessels or retraction of endfeet. Dysregulation of Aqp-4 may
be associated with cognitive dysfunction and pathology in
AD and VaD (Lan et al., 2017). In fact in chronic traumatic
encephalopathy (CTE), Aqp-4 is also increased and associated
with perivascular tau (McKee and Robinson, 2014; Babcock,
2018) or age-related tau astrogliopathy (Kovacs et al., 2017).
This similarity supports the concept the chronic damage to
the neurovascular unit may contribute to tauopathy in both
CTE and MxD.
Aquaporin-4 as a Blood Biomarker
Not only was there disruption of Aqp-4 distribution in the
brain, elevated levels of Aqp-4 protein were additionally
detected in brain-derived plasma exosomes from SHRSP/FAD
rats. As such, Aqp-4 may prove to be a useful peripheral
blood biomarker of MxD or VaD, reflecting vascular and
inflammatory changes in the brain as a result of AD pathology
with concomitant vascular dysfunction, thereby allowing for
stratification of patients with a more complex dementia and
guiding potential treatment options. In fact, others have
shown in humans that neuron-derived plasma exosomes from
traumatic brain injury (TBI) patients contain elevated levels
of Aqp-4 protein, compared to controls and that Aqp-
4 levels were significantly higher in exosomes from acute
TBI patients, compared to chronic (Goetzl et al., 2019),
suggesting that Aqp-4 levels in plasma exosomes may represent
a robust marker with which to stratify patient groups or
identify a clinically silent traumatic or indeed neurodegenerative
brain disorder. Whether the findings in our model are
relevant to serum changes in VaD or MxD patient samples
should be examined.
Evidence of Loss of Microvessel Integrity
We observed excessive accumulation of collagen IV in brains
of SHRSP/FAD rats, which may reflect the development of
cerebral SVD, which is aggravated by AD pathology. Chronic
hypertension increases collagen deposition in cerebral vessel
walls (Zhou et al., 2015) and leads to deficient vessel integrity
and function (Feihl et al., 2008; Grinberg and Thal, 2010;
Heagerty et al., 2010). Similarly dysfunctional vessels are
evident in brains of AD patients (Farkas et al., 2000; Bouras
et al., 2006; Kitaguchi et al., 2007), and other hypertensive
models with AD showed reduced vessel density (Cifuentes
et al., 2015) or leakage (Shih et al., 2018). Interestingly,
we found that SHRSP/FAD rats also showed elevations in
the endothelial cell adhesion protein platelet endothelial cell
adhesion molecule-1 (PECAM-1), which is involved with trans-
endothelial leukocyte and monocyte migration across into the
brain as part of the neuroinflammatory response (Giri et al.,
2000, 2002; Kalinowska and Losy, 2006). Elevated PECAM-1
also implies that vascular inflammatory signaling at least plays a
role in driving neuroinflammation in the brain of SHRSP/FAD
rats. Our data show that long-term mild hypertension is
associated with abnormal accumulation of vascular collagen IV,
altered PECAM-1 and disruption of astrocyte end-feet associated
with vessels. These findings suggest that AD pathology with
concurrent chronic hypertension exacerbates a loss of CNS blood
vessel integrity.
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Mitochondrial Deficits Unique to the
SHRSP/FAD Rat
Recent work has probed the involvement of dysfunctional
mitochondria and bioenergetic deficits in AD pathophysiology.
Mitochondrial dysfunction is an early event in AD pathogenesis
(Yao et al., 2009; Calkins et al., 2011; Varghese et al., 2011;
Du et al., 2012) leading to ATP depletion, which ultimately
contributes to synapse and neuron degeneration (Vos et al.,
2010; Swerdlow, 2018). In FAD rats, mitochondrial complex
I (NADH:ubiquinone oxidoreductase) but not complex II
(succinate dehydrogenase) was downregulated. The FAD effects
on complex I are consistent with findings in AD patients, in
which the 24 or 75 kDa subunits were reduced in the parietal,
occipital and temporal cortices and caudate nucleus (Kim et al.,
2001). This suggests that AD may have an early effect on
mitochondrial complex I.
The FAD rats showed no changes in complex II consistent
with reports that AD patients show no changes or even increased
complex II protein expression (Bubber et al., 2005). Apparent
increases in complex II specific to AD have been attributed to
compensatory responses facilitating anaerobic metabolism as a
result of loss of complexes, such as pyruvate dehydrogenase,
involved in oxidative metabolism. Importantly SHRSP/FAD
rats instead showed reductions in complex II, which would
be predicted to compound bioenergetic deficits. Differences in
complex II in MxD versus AD have not been looked at to the best
of our knowledge, other than one report that found no changes
in isolated VaD. However, complex II was found to be reduced
in a rat model of VaD (Singh et al., 2015) and in a traumatic
brain injury model in brain regions with disrupted cerebral
blood flow (Jiang et al., 2000). Together these data warrant
a more thorough examination of differential mitochondrial
deficits in VaD, AD and MxD to determine if additional
mitochondrial and fluorodeoxyglucose (FDG)-positron emission
tomography (PET) deficits are promoted by the coexistence of
both pathologies.
Evidence for Neuronal Damage in the
SHRSP/FAD
Hypertension appeared to amplify neurodegenerative responses
in AD rats. Here we showed that calbindin staining was
reduced in brains of hypertensive SHRSP/FAD animals, possibly
a reflection of increased neuronal vulnerability or loss as a
result of the combination of hypertension with AD pathology.
The FAD rats utilized in this study exhibit stereology-validated
neuronal loss (Cohen et al., 2013), however, the SHRSP/FAD
rats exhibited further reductions of calbindin, suggesting that
neuron or calbindin loss might be intensified in the cross.
Furthermore, caspase-cleaved actin levels were elevated in
SHRSP/FAD brain, which had previously been reported in
AD (Yang et al., 1998). Increased caspase activity may also
relate to the hyper-inflammatory environment of the brain in
SHRSP/FAD rats, through its interaction with the NOD-, LRR-
and pyrin domain-containing protein 3 (NLRP3) inflammasome,
a known hub of pathology in AD brain that drives interleukin-
1β (IL-1β) production via TLR4 signaling (Burm et al., 2015).
Although not investigated in this initial report, it will be
important for future studies to assess inflammatory receptor
signaling and cytokine profiles in the brain of SHRSP/FAD
rats and potential correlations with tau hyperphosphorylation,
tauopathy and neuron loss. Reduced brain volumes, including
for the hippocampus and temporal lobes, have been found
in individuals with elevated blood pressures, recorded several
years prior (Beauchet et al., 2013; Power et al., 2016) and in
animals in which hypertension was induced (Meissner et al.,
2017). This may be due to neuron and pericyte loss as a result
of chronic hypertension independent of tauopathy (Goel et al.,
2015; Kruyer et al., 2015). Thus, our caspase and calbindin
data add support for an amplification of neurodegenerative
responses caused by the coexistence of both pathologies
in SHRSP/FAD rats.
Pathological Elevations of NR2B in the
SHRSP/FAD Rat
We observed significant increases in hippocampal NR2B
protein detected by western blot in SHRSP/FAD rats. NR2B
is a subunit of the N-methyl-D-aspartate receptor (NMDAR),
an ionotropic glutamate receptor expressed at the post-
synaptic membrane that can enhance memory (Cao et al.,
2007; Wang et al., 2009; Vedder et al., 2013; Wang, 2014).
Although AD typically shows disproportionate loss of post
synaptic proteins, synaptic marker loss is both stage and
region dependent as there can be compensatory sprouting
which could be either pathological (aberrant sprouting) or
transiently protective and an influx of aberrant terminals
around plaques. Pathological elevations have been described
associated with apoptosis in AD models (Liu et al., 2012).
While overactivation of NR2B-containing NMDARs might
improve some aspects of hippocampal-dependent memory, it
can also contribute to excitotoxic calcium flux, hyperactivity
and to the accumulation of hyperphosphorylated tau in the
hippocampus following ischemic injury through disinhibition
of glycogen synthase kinase-3β (GSK-3β), an important tau
kinase (Xu et al., 2015). The elevated Tau pS422 staining
and CP13 protein detected in our hypertensive AD rats is
likely due to several factors, including neuroinflammation which
has been shown to drive tau pathogenesis in AD models
through effects on cytokine-induced tau hyperphosphorylation
(Ghosh et al., 2013). Under normal conditions, neurons,
but not astrocytes, express NMDARs; but following ischemic
insult, expression of NMDARs is also evident in astrocytes
(Krebs et al., 2003). Detailed longitudinal immunohistochemical
studies are required to examine the regional changes in
NR2B and phospho-NR2B and their possible relationship with
cognitive performance.
Behavioral Changes in FAD and SHRSP
Rats Were Not Exacerbated in
SHRSP/FAD Rats
Limited behavioral testing was performed, and we found that
independent effects of FAD and SHRSP were unaffected in
SHRSP/FAD by the coexistence of both features and prominently
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impacted by hyperactivity in SHRSP. In particular, hypoactivity
in the Y maze was dependent on FAD and independent of SHRSP,
while hyperactivity in both the OFT and NOR was dependent
on SHRSP and independent of FAD. Neuropsychologically, little
is understood about synergism of AD and vascular pathology
in MxD as the current criteria for MxD would require fitting
the diagnosis of both AD and VaD. For example one would
expect declarative memory deficits related to AD and executive
dysfunction relative to VaD, and predominantly with MxD
this would be occurring in the older population (averaging
83 years old) (Custodio et al., 2017). It is speculated that
the coexistence of both pathologies would lower the threshold
of dementia, whereby less AD and less vascular pathology
could cause dementia, even if neither pathology would by
itself fulfill the pathological criteria for one or the other
(Fischer et al., 1991).
There was a ceiling effect in NOR deficits, such that WKY
rats, but none of the other groups showed preference. Thus, we
could not evaluate whether the presence of hypertension affected
severity of FAD deficits using the NOR task.
Limitations in the type of behavioral testing included not being
able to complete more complex tests such as water maze or
Barnes maze, that have been used to detect cognitive impairment
in these models. We did, however, detect SHRSP-dependent
hyperactivity, which is a recognized phenotype in this model
(Gattu et al., 1997a,b; Terry et al., 2000; Hernandez et al., 2003;
Kantak et al., 2008; Meneses et al., 2011). Since patients with
MxD are typically older, another limitation in our study is that
we do not have data on progression, so we do not know if
there would be exacerbation of pathology with older ages or
with strokes which we can but did not enhance with higher
salt intake in our initial characterization. Therefore, although
we identified independent behavioral changes associated with
FAD transgene or SHRSP background with the minimal testing
done, it is important to test these rats in the future with
other behavioral tasks to determine which type of behaviors
are exacerbated by the coexistence of both hypertension and
FAD with and without higher salt intake. Future studies should
focus on behavioral tests analogous to known differences in
neuropsychological characteristics between MxD, VaD and AD
such as behavioral testing in animals that reflects differences in
episodic memory and executive function. Since VaD is associated
with more anxiety and depression (reviewed by Cerejeira et al.,
2012) we were not surprised to observe independent effects of
AD and SHRSP, but we were surprised not to see more enhanced
baseline cognitive deficits. For future studies we will explore
whether a more comprehensive neuropsychological battery,
assessing rat declarative memory (Engelmann et al., 2011) and
executive dysfunction (Beas et al., 2013) or high salt challenge
may reveal synergistic deficits caused by the hypertensive and
FAD phenotypes. Finally, in tests where SHRSP show improved
learning in young animals, a longitudinal evaluation of the
age-related decline within strains rather than comparison of
performance across strains will provide a better measure of
the relationship of age-dependent pathology with age-dependent
cognitive decline.
CONCLUSION
In conclusion, we show here that this novel rat model of
MxD exhibits robust neuropathology, including amyloid and
tau pathology, gliosis and behavioral alterations. In addition,
exacerbation of several disease parameters was noted in
SHRSP/FAD, compared to SHRSP and FAD rats, including
increased astrocytosis, Aqp-4, collagen IV deposition, PECAM-
1, caspase activity and qualitatively increased demyelination
with reduced mitochondrial enzymes and calbindin levels. This
novel model appears to be an advancement in mixed models of
dementia, which have relied primarily on major vessel occlusion
or mouse models of diabetes and AD that express Aβ but not
tau pathology. Our model more accurately reflects pathology
in the human syndrome of MxD associated with chronic
hypertension, in the absence of diabetes, developing alongside
classical amyloidogenic pathology, in addition to tauopathy
and neuron loss. Further work is needed to characterize more
completely any cognitive or behavioral abnormalities in the
SHRSP/FAD rat and also to determine the extent to which
degeneration of neurons and synapses develops in this rat with
and without salt challenge and small strokes, another hallmark
of MxD. We believe that this novel disease model will support
researchers in delineating the association between cardiovascular
abnormalities and dementia and will help bolster efforts to
develop treatments for AD, VaD and CBVD.
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